Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2006

View Archived Issues

Vaxfectin boosts seasonal influenza vaccine

ATLAS I reveals efficacy of telavancin in complicated skin and skin structure infections

PRECiSE 2 analyses, other new data on certolizumab presented

Phase I CpG-10101 results show benefit in HCV patients with relapse after response

MT-204: mAb with immunosuppressive and antiproliferative activity

Galectin-1: A receptor of anginex and target for antiangiogenic therapies

Gilead Sciences: Q3 review

CellCept misses endpoints in phase III myasthenia gravis trial

Takeda discontinues development of TAK-128

Speedel begins phase IIa study with next-generation renin inhibitor

Esperance secures USD 9 million Series A financing

MediciNova acquires antithrombic agents from Meiji Seika Kaisha

MacuSight's proprietary sirolimus formulation begins phase I study in wet AMD

Exelixis suspends enrollment in XL-999 phase II program

Ceplene MAA accepted for review

Talvesta studied for ALL in phase II

SLx-2101 has promise in cardiovascular diseases, with potential for partnering

EvoGenix to collaborate with NIH on anticancer therapeutics

TopoTarget licenses preclinical HDAC inhibitor to LEO Pharma

Xoma and Takeda collaborate on therapeutic antibody discovery and development

Termination of Tavocept license agreement for Japan

Inspire and FAES sign U.S. and Canadian agreement for bilastine

Recent patents describe new anticoagulants

Novel antiarthritic agents claimed in recent patents

Novel therapeutic agents for respiratory disorders described in recent patents

NDA filed for Somatuline Autogel

NitroMist approved for use in angina

In vitro metabolism of T-2000 presented at the AAPS meeting

First E.U. launch for Thelin in U.K.

Phytoestrogen ERr 731 shows efficacy in controlled clinical trial

Lack of toxic effects of Phytosoya isoflavone extract on the endometrium in postmenopausal women